<code id='2052813F83'></code><style id='2052813F83'></style>
    • <acronym id='2052813F83'></acronym>
      <center id='2052813F83'><center id='2052813F83'><tfoot id='2052813F83'></tfoot></center><abbr id='2052813F83'><dir id='2052813F83'><tfoot id='2052813F83'></tfoot><noframes id='2052813F83'>

    • <optgroup id='2052813F83'><strike id='2052813F83'><sup id='2052813F83'></sup></strike><code id='2052813F83'></code></optgroup>
        1. <b id='2052813F83'><label id='2052813F83'><select id='2052813F83'><dt id='2052813F83'><span id='2052813F83'></span></dt></select></label></b><u id='2052813F83'></u>
          <i id='2052813F83'><strike id='2052813F83'><tt id='2052813F83'><pre id='2052813F83'></pre></tt></strike></i>

          Wikipedia

          Wikipedia

          author:leisure time    Page View:76145
          Tome cofounders Jonathan Gootenberg, left, and Omar Abudayyeh, a scientific team that's trying to reinvent gene editing for a new era of biotech innovation.
          Suzanne Kreiter/Globe staff

          WATERTOWN — Their brainstorming began in an MIT class in 2010 when the eager undergrads shot each other emails about how to solve a bioengineering equation. It has continued for 14 years over sushi dinners, between Marvel movies, and during rowing-machine workouts.

          Together, Omar Abudayyeh, 33, and Jonathan Gootenberg, 32, have probed the mysteries of genomic editing and COVID detection. They co-published 10 scientific papers, helped launch two medical-diagnostic companies, and cofounded a Watertown startup, Tome Biosciences, that reengineers genes and cells to cure diseases. They also run the Abudayyeh-Gootenberg Lab at Harvard.

          advertisement

          Gootenberg and Abudayyeh are an unusual pair, two scientists — a Jewish American and a Palestinian American — who prefer working together in a field that often draws solitary researchers and rewards individual achievement.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          comprehensive

          Psychedelics group wrestles with new pharma identity
          Psychedelics group wrestles with new pharma identity

          OliviaGoldhill/STATDENVER—Hecouldhavebeenarockstar,areligiousicon,thewayecstaticapplausefromthousand

          read more
          Ventyx halts psoriasis drug development after lackluster trial results
          Ventyx halts psoriasis drug development after lackluster trial results

          AdobeSANDIEGO—VentyxBiosciencesreportedonMondaythatitwasendingdevelopmentofanexperimentaldrugfortrea

          read more
          Heart attack and stroke risk calculators need revising
          Heart attack and stroke risk calculators need revising

          AdobeForbusyprimarycarephysicianslikeme,anannualphysicalwitha27-year-oldmaleisablessing.Sincewe’real

          read more

          Cancer diagnosis changes perspective doctor, former hospital CEO

          CourtesyRyanPickeringPROVIDENCE–InlateAugust,Dr.JamesE.FanalewastrudgingthroughtheFalmouthRoadRace—w